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cytotoxicity [54] . Moreover, we have further improved the stability and resistance of the DNA-GNP conjugate against nuclease degradation via a new PEGylation strategy [55] . The PEGylated DNA-GNP still retained attractive properties such as high cell uptake, low/non-toxicity, high stability in biological buffers and excellent resistance to nuclease degradation, making it an attractive universal nanocarrier for intracellular delivery of DNA binding agents. However, just as other DNA-GNP system, the universally high cell uptake property made it challenging to be able to target specific cancer cells.
Herein, we report the development of a targeted, dual-stimuli-responsive nanomedicine built upon a biotin-PEG passivated i-motif DNA-GNR conjugate, Biotin-PEG-GNR-DNA/DOX (BPGDD) (Fig. 1) . The clinical anticancer drug, doxorubicin (DOX), is stably intercalated within a double-stranded i-motif DNA structure (abbreviated as dsM1/MC2, where M1 is the thiolated i-motif strand and MC2 is the complementary strand with 2 purposely introduced mismatches to tune the duplex stability) under normal physiological pH [54, 55] .
Upon exposure to weak acidic environment, the M1 strand forms a stable i-motif structure, dehybridizing the MC2 strand and triggering the release of intercalated DOX. Moreover, unlike previous DNA-GNP designs where GNP mostly acts as a stable nanoscale scaffold, the GNR here also efficiently absorbs and converts NIR-radiation into localized photothermal heating to facilitate NIR-light triggered drug release, presumably via heat induced dsM1/MC1 dehybridization. The nanocarrier was further passivated by a thiolated poly(ethylene glycol) biotin (PEG-biotin) to increase stability, prolong blood half-life and reduce toxicity and immunogenicity.
The incorporation of biotin also allows the carrier to bind specifically to cancer cell over-expressed biotin receptors for specific cancer cell targeting. BPGDD complexes are characterized and their pH-and NIR radiation dependent DOX release properties are evaluated. Their cell uptake and efflux properties as well as cytotoxicities are evaluated using both drug-sensitive and MDR human breast adenocarcinoma cell lines (MCF-7 and MCF-7/ADR). We show this GNR based multifunctional BPGDD nanomedicine can provide effective, targeted treatment of MDR MCF-7/ADR cancer cells. Fig. 1 . BPGDD is effectively taken up by cancer cell via binding to its over-expressed biotin receptors and entry into intracellular endosomes. The gradual acidification of the intracellular compartments following the natural endosomal maturation/trafficking pathways lead to i-motif formation and trigger DOX release.
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Alternatively, DOX release can also be triggered by application of a NIR radiation to locally heats up the GNR carrier.
Materials and methods
Materials
Mercaptoethylamine, dimethyl sulfoxide (DMSO), cetyltrimethylammonium bromide (CTAB), 7-Bromo-3hydroxy-2-naphthoic acid (7-BrHNA), sodium borohydride (NaBH4), silver nitrate (AgNO3), L-ascorbic acid (L-AA), 3-(4,5-dimethylthiazol-2-yl) - 
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vigorous stirring for 60 s, the seed solution was injected into the growth solution. The resulting mixture was stirred for 30 s and left standing overnight for GNRs growth. The reaction products were isolated by centrifugation at 10000 rpm for 20 min followed by removal of the supernatant. The precipitates were redispersed in 1 mL of water.
Synthesis of 11-mercaptoundecanoic acid (MUDA) capped GNRs
The CTAB surfactants on the GNR surface were replaced through the round-trip phase transfer ligand exchange reported by Wijaya et al [59] . Specifically, 1 mL of 20-50 nM GNRs-CTAB in water was put into contact with 1 mL of dodecanethiol (DDT). Then 3 mL of acetone was added and the solution was swirled for a few seconds to extract GNRs into DDT, upon which the aqueous phase became clear. Next, GNR-DDT were diluted in 5 mL of toluene to remove excess DDT, centrifuged at 8000 rpm for 15 min, and then resuspended in 1 mL of toluene by sonication. The GNR-DDT in toluene were then added to 9 mL of 0.01 M mercaptoundecanoic acid (MUDA) in toluene at 70 °C and vigorously stirred. Refluxing and stirring continued until visible aggregation was observed (in 15 min), and then the solution was allowed to settle and cool to room temperature. The aggregates were washed twice with 1 mL of toluene via decantation and then once with 1 mL of isopropanol to deprotonate the carboxylic acid. The aggregates spontaneously re-dispersed in 1× tris-borate-EDTA (TBE) buffer.
Synthesis of HS-PEG
To synthesize HS-PEG ( Fig. 3A. ), 3-mercaptopropionic acid (MPA) was first activated with EDC to enhance the conjugation efficiency, through reaction with EDC, HOBT and DMAP at the molar ratio MPA: EDC: HOBT: DMAP of 1: 2: 2: 0.2 in 5 mL of DMSO under a N 2 atmosphere for 4 h at room temperature. The activated MPA was then added to 2 mL of 1 mM mPEG2000 in DMSO and the mixture was stirred under N 2 atmosphere for 48 h. Then, the products were dialyzed for 2 days using a dialysis tube (molecular weight cut-off = 1000 Da)
to remove unreacted materials. The resulting HS-PEG was obtained after freeze drying and its chemical structure was confirmed by the 1 H-NMR spectra recorded on a Varian Mercury Plus-400 NMR spectrometer (Varian, USA).
Synthesis of HS-PEG-Biotin
The synthesis route of HS-PEG-Biotin was shown in Fig 
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Preparation of HS-DNA/DOX
To synthesize HS-DNA/DOX, M1 was mixed with MC2 at the molar ratio of 1:1 in 500 μL of MES buffer (50 mM MES, 150 mM NaCl, pH 7.4) and hybridized for 4 h at 37 °C to form dsDNA, which were then titrated into DOX in MES buffer [53] . Different molar ratios of DNA base pair to DOX were used to determine the optimized DOX loading condition. The change of DOX fluorescence intensity was monitored using a F-7000 fluorescence spectrophotometer (Hitachi, Japan) to evaluate DOX-dsDNA binding.
Synthesis of Biotin-PEG-GNR-DNA/DOX (BPGDD) nanocarrier
GNR-MUDA and HS-PEG were mixed at the molar ratio of 1:50,000 and stirred for 48 h under N 2 atmosphere.The resulting GNR-PEG was centrifuged at 10,000 rpm for 20 min and then washed twice with water to remove any residual reactants. The GNR-PEG precipitates were re-dispersed in 1 mL of water. Then, HS-DNA/DOX and HS-PEG-Biotin (at a molar ratio of 10:1) were dissolved in 4 mL of water, followed by addition of 1 mL of GNR-PEG and stirring for 48 h under a N 2 atmosphere. The resulting Biotin-PEG-GNR-DNA was purified by centrifugation, washed and re-dispersed in 1 mL of water. Finally, Biotin-PEG-GNR-DNA and DOX were incubated for 4 h at the molar ratio of 1:40,000. The resulting Biotin-PEG-GNR-DNA/DOX (BPGDD) nanocarrier was obtained after centrifugation and re-dispersed in 1 mL of water.
Absorbance of the GNRs was measured using a U-2910 UV-Vis-NIR spectrophotometer (Hitachi, Japan).
Zeta potential was measured using a Zetasizer NanoZS/ZEN3600 (Malvern Instruments, Herrenberg, Germany). Morphology and size were measured using a JEOL JEM-2100F transmission electron microscope (TEM) (Japan). The solution temperatures were detected with a HH508 digital thermometer (Omega, Switzerland), and concentrations of DOX released were detected with a fluorescence spectrophotometer as mentioned above.
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Cell culture
The human breast adenocarcinoma cell line MCF-7 and the ADR-resistant breast cell line MCF-7/ADR were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were trypsinized using trypsin-EDTA and maintained in a humidified atmosphere supplemented with 5% CO 2 at 37 °C.
Cellular uptake
MCF-7 and MCF-7/ADR cells were seeded into 24-well plates at a density of 1.5x10 5 cells per well and cultured for 24 h at 37 °C. The cells were then treated with free DOX, GNR-DNA/DOX (GDD) and BPGDD at 0.25 μM DOX concentration in1640 medium without FBS for various durations of time. Untreated cells served as a negative control. Then cells were washed three times with cold PBS and fixed with 4% paraformaldehyde solution. The cellular uptake was quantitatively determined by a BD LSRFortessa flow cytometry (Becton Dickinson, USA). The mean fluorescence signal for 10,000 cells was recorded and all experiments were repeated three times.
Efflux studies
MCF-7/ADR cells were seeded into 24-well plates and cultured for 24 h. The spent medium was removed and the cells were incubated with free DOX, GDD and BPGDD at 2 μM DOX concentration in 1640 medium without FBS. After for 4h, the cells were washed twice by PBS and then replenished with a fresh complete medium. After incubation for a specific duration of time ranging from 0.5 to 8 h, the cells were washed three times with cold PBS and fixed with 4% paraformaldehyde solution. The cellular efflux was quantitatively determined by flow cytometry.
Cellular accumulation under NIR irradiation
The photothermal effect was evaluated by following previously established procedures. MCF-7/ADR cells were incubated with BPGDD at 2 μM DOX concentration in1640 medium without FBS for 4 h, washed three times with cold PBS, and then replenished with a fresh complete medium. Half of cells were irradiated at 808 nm with a 5 mm diameter spot-size at 5 W/cm 2 for 10 or 30 min and the other half did not undergo laser irradiation. After incubation for an additional 1 or 4 h, the spent medium was removed and cellular apoptosis was quantitated by flow cytometry.
Co-localization visualized by confocal laser scanning microscope (CLSM)
A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT
To observe the intracellular distribution of the nanocarrier, MCF-7/ADR cells were seeded into 12-well glassbottom plates at a density of 1 x 10 5 cells/well and cultured for 24 h. The cells were then treated with free DOX, GDD and BPGDD at 2 μM DOX concentration. After 2 or 4 h of incubation, the spent medium was aspirated and cells were washed twice with PBS and replenished with a fresh complete medium. Half of cells treated with BPGDDX complexes were irradiated at 808 nm with a 5 mm diameter spot-size at 5 W/cm 2 for 30 min.
Afterwards, cells were treated with Hoechst 33342 (6 μg/mL) for 20 min, washed with PBS twice, and fixed with 500 μL of 4% paraformaldehyde for 30 min. The fixed cells were sealed with slides and observed using a confocal laser scanning microscope (TCS SP5, Leica, Germany).
Evaluation of cytotoxicity
Cytotoxicity of nanocarriers toward cells was assessed using the MTT assay. Firstly, MCF-7 and MCF-7/ADR cells were seeded into 96-well plates at a density of 4x10 3 Table 1 DNA sequence of M1,MC2
Results and Discussion
Synthesis and characterization of BPGDD
The pH-dependent DOX binding properties of double-stranded (ds) M1/MC2 (see Fig.2A for the principle of pH-triggered drug delivery and Table 1 for the sequences) structure was investigated. As shown in Fig. 2B , a sharp decrease of DOX fluorescence intensity was observed with increasing amounts of dsM1/MC2 being added to free DOX solution at pH 7.4, indicating that DOX was intercalated efficiently to the DNA duplex. Fig.   S3 shows the DOX fluorescence quenching saturate at dsM1/MC2:DOX molar ratio of ~0.12, suggesting each dsM1/MC2 can bind up to 8 DOX molecules.
DNA code Sequece(5' 3') M 1 HS-TTT TTT TTT TCC CTA ACC CTA ACC CTA ACC C MC 2 GT GTT AGG TTT AGG GTT AGG G Dependence of DOX fluorescence intensity as a function of pH for the dsDNA/DOX and BPGDD systems respectively. Figure 3 show the schematics of our approach to prepare GNR based nanocarriers. Briefly, GNR with an aspect ratio of ~3.5 was prepared by a seed-mediated growth method using cetyltrimethyl ammonium bromide
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(CTAB) surfactants as reported previously [58] . It was then treated with excess 11-mercapto-undecanoic acid (MUDA) to completely display surface CTAB surfactants to yield GNR-MUDA. This was supported by a complete reversal of zeta potential from +40.2 mV to -42.8 mV (Fig.4B ), suggesting the positively-charged CTAB surfactants were completely displaced by the negatively-charged MUDA. GNR-MUDA was then treated with a thiolated-PEG/PEG-biotin (The 1 H-NMR spectra are presented in Fig.S1, Fig. S2 . The peak at 2.04 ppm is from the proton of SH), displacing some of GNR surface MUDA ligands to form GNR-PEG. This was evidenced by a reduction of negative zeta potential to -24.3 mV because PEG ligand was neutral. The GNR-PEG and BPGDD. GNR-CTAB showed a TSPR peak at 512 nm and an LSPR peak at 806 nm, suggesting it was an excellent absorption agent for 808 nm NIR radiation. Compared to native GNR, there were negligible changes in UV-Vis-NIR absorption spectra of GNR-MUDA, GNR-PEG and BPGDD, indicating that the surface modifications did not significantly change the unique optical properties of GNRs [60, 61] . The TEM image of BPGDD (Fig. 4C ) showed typical rod shaped GNRs with an average length of 50 ± 5 nm and diameter of 14 ± 3 nm, giving an aspect ratio of ~3.5 . Fig. 4D shows the pH-dependent release properties of DOX from dsM1/MC2/DOX and BPGDD systems.
The dsDNA/DOX started to release DOX at pH <6.0 with a half-release pH of ~5.4, in good agreement with the literature result [54] . The DOX release from dsM1/MC2/DOX happed very rapidly, saturated DOX release was completed in 30 seconds after pH change. Interestingly, BPGDD system displayed a shifted pHdependent DOX release character: the onset of DOX release happed at pH ~6.5 with the half-release pH of ~5.8, suggesting it is well-suited for early endosomal release (typical pH 6.0-6.8). 
In vitro pH and NIR laser triggered DOX release
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were almost identical ( Fig. 5D ), suggesting that NIR irradiation did not affect DOX fluorescence. Fig. 5F revealed that solution temperature was raised rapidly with an increasing NIR radiation power density [62] [63] [64] , confirming that GNR complexes could convert NIR light energy into heat efficiently and quickly. The increased temperature could dehybridize dsM1/MC2, facilitating DOX release, e.g. NIR-radiation could act as a second stimulus to trigger DOX release. This was proved to be true, where the combination of NIR laser radiation and low environmental pH (5.0) achieved accumulative DOX release of 49.6%, 52.3%, 66.8%, 77.5% and 89.5%
with a laser power density of 1, 2.5, 5, 7.5 and 10 w/cm 2 over 30 min, respectively (Fig. 5E) . These values were significantly higher than that achieved by using pH 5.0 alone (see Fig.5C ), confirming that DOX release inside cells can be improved by combined effect of pH decrease and NIR radiation. Data are presented as mean ± SD (n = 3).
Cellular uptake and efflux
The cellular uptake of free DOX, GNR-DNA/DOX (GDD, only dsDNA/DOX loaded GNR) and BPGDD by MCF-7 ( Fig. 6A) and MCF-7/ADR cells (Fig. 6B) was examined by flow cytometry. As shown in Fig. 6A , the lowest level of cellular uptake of free DOX by MCF-7 cells was observed and it increased gradually with incubation time. When the cells were treated with GDD, intracellular DOX level was found to be 3.4-or 2.4fold that of the free DOX treated cells after 0.5 or 24 h incubation, respectively. BPGDD treated cells exhibited the highest intracellular DOX accumulation, which was 3.9-fold or 4.1-fold that of free DOX treated cells with 0.5 h or 24 h. These results revealed that biotin-modified BPGDD significantly increased DOX accumulation inside cancer cells. Fig.6B revealed that mean DOX fluorescence intensity of free DOX treated MDR MCF-7/ADR cell (66.5 after 24 incubation) was substantially lower than that in the drug sensitive MCF-7 cells (155).
Moreover, it did not changed significantly throughout the 24 h treatment period, confirming that the MCF- A key cell MDR mechanism is efficient drug efflux by its surface over-expressed efflux pumps (e.g. gglycoproteins), preventing intracellular drug accumulation and compromising treatment efficacy. Here the drug efflux properties were measured by monitoring the retained cellular DOX fluorescence after 4 h treatment with free DOX, GDD or BPGDD during further incubation with fresh medium (Fig.6C and 6D) . The normalized the intracellular DOX fluorescence intensities in MCF-7 cells were decreased continuously during the further incubation period, but the downward trends were slower for cells treated by GNR-based nanomedicines than by free DOX. For MDR MCF-7/ADR cells, the intracellular DOX fluorescence decreased much faster than that in MCF-7 cells. This was especially evident for free DOX treatment where only ~38% of original DOX fluorescence was retained after 0.5 h further incubation (versus ~ 72% for MCF-7 cells). These results suggested that the over-expressed efflux transporters on MCF-7/ADR cell surface were efficient at pumpingout intracellular DOX molecules, preventing their built up. The slower DOX efflux rates observed for the GNRbased treatments were presumably due to deeper drug delivery afforded by nanocarriers, making cell-surface efflux transporter less effective.
Moreover, MCF-7/ADR cells after incubation with BPGDD for 4 h followed by NIR radiation at 5 W/cm 2 for 0 (control), 10 and 30 min and further incubated in fresh media at 37 °C for another 1 or 4 h were also
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investigated. Interestingly, cells after treatment with NIR radiation displayed significantly higher intracellular DOX fluorescence intensity (increasing from 1191 to 2757 and 3880 (a.u.) with 10 and 30 min irradiation, respectively), suggesting a substantially increased DOX concentration at the cell interior, presumably due to combined effects of more effective DOX release (as observed in Fig. 5 ) and significantly compromised DOX efflux ability after NIR laser treatment. 
Confocal imaging BPGDD intracellular delivery to breast cancer
GNR-mediated intracellular DOX distribution was investigated in MCF-7/ADR cells by confocal laser
scanning microscopy (CLSM). Fig. 7A showed that when MCF-7/ADR cells were incubated with free DOX (2 μM), only very weak DOX fluorescence was found inside the cells. However, a significantly enhanced intracellular DOX fluorescence was observed for cells treated with GDD and BPGDD, respectively. Moreover, cells treated with BPGDD displayed stronger intracellular DOX fluorescence than those treated by GDD,
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suggesting biotin-modification on BPGDD significantly increased their uptake by MDR breast cancer cellline.
What's more, the DOX fluorescence also increased with the increasing incubation time, presumably due to a gradual uptake and release of DOX payload following a gradually acidified intracellular endo-/lyso-somal environments. Importantly, when cells were treated with NIR irradiation after 4 h uptake of BPGDD, almost all DOX fluorescence was localized in the nucleus, producing almost perfectly overlapped purple-fluorescent spots in merged images. The cross sectional analysis of the above fluorescence image (Fig.7B ) further confirmed the perfect red (DOX) and blue (nuclei) fluorescence overlap, suggesting NIR radiation facilitated the trafficking of DOX into the cell nucleus. This observation may be due to the increased DOX release and enhanced cell membrane permeability induced by GNR based photothermal heating [65] . In vitro cytotoxicity of various GNR-based nanomedicines towards MCF-7 and MCF-7/ADR cells was investigated by MTT assay (see Fig.8 ) and the IC50 value (the concentration that inhibited cell growth by 50%) was calculated ( Table 2) . MCF-7/ADR cells displayed a very high IC50 value (251 μM) of free DOX treatment, which was 1192-fold higher than the parent MCF-7 cells (IC50=0.21 μM), consistent to the low DOX accumulation and high efflux ability as observed previously due to over-expressed efflux transporters. Table 2 reveled that GDD and BPGDD showed similar IC50 values (0.17 and 0.06 μM respectively) to free DOX towards MCF-7 cells. However, the corresponding IC50 values toward MCF-7/ADR cells (9.5 and 3.4 μM for
Cytotoxictiy evaluation
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GDD and BPGDD, respectively) were 26-and 67-fold lower than that for free DOX, suggesting the GNR based nanomedicine formulation greatly improved cytotoxicity of DOX toward MDR cells. The greatly increased cytotoxicity here was fully consistent with the significantly increased cellular uptake and reduced drug efflux of the BPGDD as observed in Fig.6 . Table 2 The IC50 and resistance reversion index(RRI) of Free DOX, GDD and BPGDD against MCF MCF-7/ADR cells. Resistance reversion index (RRI), ratio of IC50 of free DOX solution to nanomedicincs, RRI=IC50(free DOX)/IC50(GDD or BPGDD)
The cytotoxicity of free DOX, Biotin-PEG-GNR and BPGDD (contain 2 μM DOX) towards MCF-7/ADR cells induced by photothermal heating was assessed by MTT assay. Fig. 8C showed that NIR irradiation of free DOX treated MCF-7/ADR cells showed negligible effect on cell viability. Similarly, NIR irradiation of Biotin-PEG-GNR treated cells did not produce any significant increase of inhibition rate either, suggesting that the photothermal heating alone generated by the NIR radiation here was below cell killing threshold. Fig. 8E compared the inhibition rates of BPGDD treated MCF-7/ADR cells with different NIR radiation conditions. Applying 2.5 w/cm 2 NIR irradiation for up to 30 min produced negligible changes of the BPGDD cytotoxicity.
Increasing the power density to 5 w/cm 2 produced a radiation-time dependent significantly increased inhibition rate towards MCF-7/ADR cells, where 81% inhibition rate was obtained with 30 min radiation, which is more than twice that without NIR irradiation. Further increasing the laser power density to 7.5 w/cm 2 produced a more rapid result, where a 5 min radiation led to 78% cell inhibition rate. This observation was in good agreement with the findings from the temperature increase experiment of the BPGDD solution in response to NIR irradiation at different power densities. 5 min radiation at 7.5 w/cm2 was able to produce a greater temperature increase than that at 5.0 w/cm2 for 30 min (see Fig. 5F ). The impressive cell inhibition rate with NIR laser radiation was mainly due to NIR radiation triggered efficient DOX release and trafficking into the cell nucleus, leading to the greatly enhanced cell-killing activity [65] . Annexin-V/propidium iodide (PI) double staining was performed to determine cell apoptosis. As shown in Fig.9 , the percentage of apoptotic cells (sum of late apoptosis percentage (Q2) and early apoptosis percentage (Q3)) was 18.5% (Q2 and Q3, 4.93% and 13.6%) when MCF-7/ADR cells were treated with free DOX. It was increased to 28.7% (Q2 and Q3, 6.58% and 22.1%) and 40.3% (Q2 and Q3, 11.5% and 28.8%) when cells were treated with GDD and BPGDD, respectively, consistent to the enhanced drug delivery and controlled release of DOX into the cell interior by the GNR-DNA carriers as observed in cell uptake studies.
Upon treatment with the BPGDD for 4 h and then exposure to NIR irradiation at 5 W/cm 2 for 30 min, the percentage of apoptotic cells reached 86.6%, further confirming the previous results that the NIR irradiation significantly increased cell apoptosis rate [66, 67] .
Conclusions
In conclusion, we have developed a pH-responsive DNA-GNR based nanomedicine that offers convenient loading of a model clinical chemotherapeutic drug (DOX) in native format via intercalation while allows for pHand NIR-light dual-stimuli-trigged efficient drug release. Biotin-PEG functional of the GNR nanomedicine has
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greatly increased its cell uptake and reduced the drug efflux ability by multidrug resistance MCF-7/ADR cells.
Moreover, NIR-laser radiation has found to not only increase the DOX release, but also facilitate the drug's nucleus accumulation. As a result, this multifunctional nanomedicine substantially enhanced the cytotoxicity (by 67 fold) of free DOX towards multidrug resistance MCF-7/ADR cells. Combining abilities of targeted delivery, controlled dual-stimuli-responsive release and photothermal therapy, this DNA-GNR based multifunctional nanomedicine appears to be a highly promising, effective anticancer nanomedicine for treatment of multidrug resistant cancer at cellular or even in vivo levels. Alternatively, DOX release can also be triggered by application of a NIR radiation to locally heats up the GNR carrier. 
